Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018926 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02018926 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT02018926, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a hypomethylating agent (HMA) used to treat MDS. In this study, patients with intermediate- or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the safety of the study treatment. Safety assessments will include echocardiograms, electrocardiograms and routine safety laboratory studies (hematology and serum chemistry). In addition, clinical response to treatment will be monitored using bone marrow aspirates or biopsies, and other routine methods.
Interventions
- DRUG Azacitidine
- DRUG Mocetinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02018926
The ClinicalTrials.gov registry entry for NCT02018926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT02018926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02018926 about?
NCT02018926 is a clinical study titled "Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS". Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a hypomethylating agent (HMA) used to treat MDS. In this study, patients with intermediate- or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the safety of the study treatm...
What is the current status of trial NCT02018926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02018926?
The interventions under investigation include: Azacitidine (DRUG), Mocetinostat (DRUG).
Who is sponsoring clinical trial NCT02018926?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.